Literature DB >> 9597930

Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma.

D Simon1, J Koehrle, C Reiners, A R Boerner, C Schmutzler, K Mainz, P E Goretzki, H D Roeher.   

Abstract

During the course of tumor progression the differentiated morphologic and functional characteristics of differentiated thyroid carcinomas (DTC) disappear. This corresponds to more aggressive growth, metastatic spread, and loss of iodine uptake. Experimental data give strong evidence that differentiated functions of iodine metabolism can be reinduced by retinoic acids. Results of a study performed in patients with advanced DTC are presented. Twenty patients with DTC (eight follicular, seven papillary, five oxyphilic) were selected for treatment with retinoic acid 1.5 mg/kg body weight/day over 5 weeks. All patients had advanced tumor stages with prior operative and radioiodine treatment. Extensive tumor invasion, distant metastatic spread, or insufficient or no radioiodine uptake precluded any conventional therapeutic option. The aim was to assess the changes under retinoid treatment. Iodine uptake increased in eight patients (three follicular, three papillary, two oxyphilic). Thyroglobulin (TG) as parameter for tumor mass and differentiation increased in 12 (63%) patients, decreased in 6 (32%), and did not change in 1 (5%). Retinoids do have an effect on differentiation status of DTC, reinducing iodine uptake in 50% of patients. TG levels do not always parallel a response in iodine uptake.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597930     DOI: 10.1007/s002689900436

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  23 in total

Review 1.  The management of metastatic differentiated thyroid carcinoma.

Authors:  S I Sherman
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  Alternative medical treatment for radioiodine-refractory thyroid cancers.

Authors:  Jin Chul Paeng; Keon Wook Kang; Do Joon Park; So Won Oh; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2011-09-17

Review 3.  [Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-01-15

4.  Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line.

Authors:  T Kogai; J J Schultz; L S Johnson; M Huang; G A Brent
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

5.  Anaplastic thyroid carcinoma: a therapeutic dilemma.

Authors:  Hang-Seok Chang; Kee-Hyun Nam; Woung Youn Chung; Cheong Soo Park
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

Review 6.  [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].

Authors:  C Spitzweg
Journal:  Internist (Berl)       Date:  2003-04       Impact factor: 0.743

7.  Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.

Authors:  Barbara Jarzab; Daria Handkiewicz-Junak; Józef Roskosz; Zbigniew Puch; Zbigniew Wygoda; Aleksandra Kukulska; Beata Jurecka-Lubieniecka; Kornelia Hasse-Lazar; Maria Turska; Aleksander Zajusz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-29       Impact factor: 9.236

8.  Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma.

Authors:  S Mendes Coelho; R Corbo; A Buescu; D P Carvalho; M Vaisman
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

Review 9.  Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma.

Authors:  June-Key Chung; Hye Won Youn; Joo Hyun Kang; Ho Young Lee; Keon Wook Kang
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

10.  13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study.

Authors:  Daria Handkiewicz-Junak; Jozef Roskosz; Kornelia Hasse-Lazar; Sylwia Szpak-Ulczok; Zbigniew Puch; Aleksandra Kukulska; Tomasz Olczyk; Andrzej Piela; Ewa Paliczka-Cieslik; Barbara Jarzab
Journal:  Thyroid Res       Date:  2009-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.